Hostname: page-component-848d4c4894-wg55d Total loading time: 0 Render date: 2024-05-28T06:29:03.718Z Has data issue: false hasContentIssue false
  • English
  • Français

Sublingual sufentanil for incident pain and dementia-related response agitation

Published online by Cambridge University Press:  25 February 2011

Michael J. Passmore
Michael J. Passmore*
Affiliation:
Division of Geriatric Psychiatry, University of British Columbia, Vancouver, BC, Canada
*
Correspondence should be addressed to: Michael J. Passmore, University of British Columbia, Division of Geriatric Psychiatry, c/o Mount St. Joseph Hospital, Ward 1 South 3080 Prince Edward St., Vancouver, B.C., V5T 3N4, Canada. Phone: +1 604-874-1141 ext: 78230; Fax: +1 604-877-8157. Email: passmoremd@gmail.com.
Get access Rights & Permissions [Opens in a new window]

Abstract

Patients with moderate to severe dementia commonly exhibit agitation and aggression in response to personal care. Incident pain is a common factor underlying response agitation that in turn can obstruct the delivery of essential nursing care. Medications commonly used to manage response agitation have specific risks in patients with dementia. This report details the case of a patient suffering from severe dementia with incident pain and response agitation that remitted with the use of sublingual sufentanil, a rapid-onset and ultra-brief acting opioid analgesic.

Keywords

BPSDpalliative carebehavioraggressionopioidnursingAlzheimer's disease
Type
Case Report
Information
International Psychogeriatrics , Volume 23 , Issue 5 , June 2011 , pp. 844 - 846
Copyright
Copyright © International Psychogeriatric Association 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Herrmann, N. and Gauthier, S. (2008). Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. Canadian Medical Association Journal, 179, 1279–1287.CrossRefGoogle ScholarPubMed
Kunik, M. E. et al. (2010). Causes of aggressive behavior in patients with dementia. Journal of Clinical Psychiatry, 71, 1145–1152.CrossRefGoogle ScholarPubMed
Palmer, P. P., Hamel, L. G. and Skowronski, R. J. (2009). Single- and repeat-dose pharmacokinetics of sublingual sufentanil nanotab in healthy volunteers. Poster A1222 – Proceedings of the 2009 Annual Meeting of the American Society Anesthesiologists. New Orleans, 17–21 October.Google Scholar
Passmore, M. J., Gardner, D. M., Polak, Y. and Rabheru, K. (2008). Alternatives to atypical antipsychotics for the management of dementia-related agitation. Drugs and Aging, 25, 381–398.CrossRefGoogle ScholarPubMed
Reisfield, G. M. and Wilson, G. R. (2007). Rational use of sublingual opioids in palliative medicine. Journal of Palliative Medicine, 10, 465–475.CrossRefGoogle ScholarPubMed
Sampson, E. L. et al. (2011). Palliative assessment and advance care planning in severe dementia: an exploratory randomized controlled trial of a complex intervention. Palliative Medicine [e-journal] 12 January 2011.CrossRefGoogle Scholar
Scholz, J., Steinfath, M. and Schulz, M. (1996). Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Clinical Pharmacokinetics, 31, 275–279.CrossRefGoogle ScholarPubMed
US Food and Drug Administration (2005). Public Health Advisory. Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. 11 April. Silver Spring, MD: Food and Drug Administration.Google Scholar